Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis.
- 1Department of Pharmacy, Peking University First Hospital, Beijing, China.
- 2School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Abstract
Trilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor administered before chemotherapy, reduces chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), but its efficacy across solid tumors remains unclear. This meta-analysis evaluated the efficacy and safety of trilaciclib in solid tumor patients receiving chemotherapy. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to January 21, 2026. Randomized controlled trials (RCTs) and cohort studies comparing chemotherapy with or without trilaciclib were included. Primary outcomes were severe neutropenia (SN), febrile neutropenia (FN), duration of severe neutropenia (DSN), Grade 3/4 leukopenia, and granulocyte colony-stimulating factor (G-CSF) use. Secondary outcomes included other hematologic toxicities, supportive care interventions, and efficacy outcomes. Ten studies involving 1172 patients (six RCTs and four cohort studies) were identified. Trilaciclib significantly reduced SN (OR, 0.14; 95% CI, 0.06-0.31; p < 0.001), FN (OR, 0.19; 95% CI, 0.11-0.36; p < 0.001), Grade 3/4 leukopenia (OR, 0.25; 95% CI, 0.13-0.46; p < 0.001), and G-CSF use (OR, 0.36; 95% CI, 0.18-0.71; p = 0.0087), and shortened DSN (MD, -2.30 days; 95% CI, -4.28 to -0.31; p = 0.0309). It also reduced Grade 3/4 anemia and thrombocytopenia and decreased use of erythropoiesis-stimulating agents, red blood cell transfusions, and platelet transfusions. Overall survival showed a borderline improvement (HR, 0.84; 95% CI, 0.71-0.99; p = 0.0373), while no significant differences were observed in progression-free survival, overall response rate, or non-hematologic adverse events. Subgroup analyses suggested greater benefit in ES-SCLC. Overall, trilaciclib before chemotherapy significantly reduced CIM and supportive care needs, with no apparent compromise in antitumor efficacy and more pronounced effects in ES-SCLC.
Related
- Efficacy and toxicities of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for unresectable pancreatic cancer: a systematic review and meta-analysis
- Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
- Predicting the risk of chemotherapy-induced myelosuppression in clinical practice: an interpretable machine learning approach based on routine laboratory data
- The efficacy of ginger for treating chemotherapy-induced nausea and vomiting in patients with cancer: a systematic review and meta-analysis
- The efficacy and safety of neoadjuvant chemotherapy plus immune check point inhibitors for locally advanced cervical cancer: a systematic review and meta-analysis.
BibTeX
@article{tian2026efficacy,
title = {{Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis.}},
author = {Wei Tian and Qianxin Liu and Ying Zhou and Zhuo Zhang},
journal = {Thoracic cancer},
year = {2026},
month = oct,
doi = {10.1111/1759-7714.70402},
url = {https://europepmc.org/article/MED/42876373},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta-Analysis.
AU - Wei Tian
AU - Qianxin Liu
AU - Ying Zhou
AU - Zhuo Zhang
PY - 2026
DA - 2026/10/01
JO - Thoracic cancer
DO - 10.1111/1759-7714.70402
UR - https://europepmc.org/article/MED/42876373
AB - Trilaciclib, a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor administered before chemotherapy, reduces chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), but its efficacy across solid tumors remains unclear. This meta-analysis evaluated the efficacy and safety of trilaciclib in solid tumor patients receiving chemotherapy. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to January 21, 2026. Randomized controlled trials (RCTs) and cohort studies comparing chemotherapy with or without trilaciclib were included. Primary outcomes were severe neutropenia (SN), febrile neutropenia (FN), duration of severe neutropenia (DSN), Grade 3/4 leukopenia, and granulocyte colony-stimulating factor (G-CSF) use. Secondary outcomes included other hematologic toxicities, supportive care interventions, and efficacy outcomes. Ten studies involving 1172 patients (six RCTs and four cohort studies) were identified. Trilaciclib significantly reduced SN (OR, 0.14; 95% CI, 0.06-0.31; p < 0.001), FN (OR, 0.19; 95% CI, 0.11-0.36; p < 0.001), Grade 3/4 leukopenia (OR, 0.25; 95% CI, 0.13-0.46; p < 0.001), and G-CSF use (OR, 0.36; 95% CI, 0.18-0.71; p = 0.0087), and shortened DSN (MD, -2.30 days; 95% CI, -4.28 to -0.31; p = 0.0309). It also reduced Grade 3/4 anemia and thrombocytopenia and decreased use of erythropoiesis-stimulating agents, red blood cell transfusions, and platelet transfusions. Overall survival showed a borderline improvement (HR, 0.84; 95% CI, 0.71-0.99; p = 0.0373), while no significant differences were observed in progression-free survival, overall response rate, or non-hematologic adverse events. Subgroup analyses suggested greater benefit in ES-SCLC. Overall, trilaciclib before chemotherapy significantly reduced CIM and supportive care needs, with no apparent compromise in antitumor efficacy and more pronounced effects in ES-SCLC.
SN - 1759-7706
SN - 1759-7714
ER -